Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Stock

Key Points

• Insider Tobin Juvenal sold 3,288 Castle Biosciences shares for about $107,419 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 8.46% to 35,565 shares.
• Castle Biosciences reported quarterly EPS of -$0.13, beating analyst estimates of -$0.35, and revenue of $101.95 million, above the $92.76 million consensus.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $46.50; recent targets ranged from $40 to $52.

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 3,288 shares of the company's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $32.67, for a total transaction of $107,418.96. Following the completion of the transaction, the insider owned 35,565 shares of the company's stock, valued at approximately $1,161,908.55. The trade was a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL stock traded up $0.51 on Thursday, hitting $34.50. 440,800 shares of the stock traded hands, compared to its average volume of 398,699. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -44.81 and a beta of 1.00. Castle Biosciences, Inc. has a 52 week low of $17.72 and a 52 week high of $44.28. The firm has a 50 day simple moving average of $34.30 and a two-hundred day simple moving average of $28.42. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.28 and a quick ratio of 5.12.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.22. The company had revenue of $101.95 million for the quarter, compared to analysts' expectations of $92.76 million. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. As a group, equities research analysts predict that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Institutional Trading of Castle Biosciences

Several hedge funds have recently bought and sold shares of CSTL. BlackRock Inc. purchased a new position in shares of Castle Biosciences during the second quarter valued at about $78,513,000. Jefferies Financial Group Inc. bought a new position in Castle Biosciences during the second quarter valued at approximately $15,440,000. AIGH Capital Management LLC bought a new position in Castle Biosciences during the second quarter valued at approximately $13,001,000. Renaissance Technologies LLC grew its holdings in Castle Biosciences by 8.1% during the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company's stock valued at $13,080,000 after buying an additional 39,700 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Castle Biosciences during the 2nd quarter valued at approximately $7,912,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on CSTL. Weiss Ratings reiterated a "sell (d-)" rating on shares of Castle Biosciences in a research report on Thursday, October 29th. BTIG Research boosted their price target on Castle Biosciences from $44.00 to $52.00 and gave the stock a "buy" rating in a report on Monday. Robert W. Baird upped their price target on Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a research note on Monday. Wall Street Zen raised shares of Castle Biosciences from a "hold" rating to a "buy" rating in a report on Sunday, November 1st. Finally, KeyCorp increased their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company an "overweight" rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Castle Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $46.50.

Castle Biosciences Company Profile

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company's portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett's esophagus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.